Alliance A022102: Randomized phase III trial of mFOLFIRINOX plus /- nivolumab vs. FOLFOX plus /- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)

被引：0
|
作者：
Park, Haeseong
Geyer, Susan Michelle
Klute, Kelsey
Bleeker, Jonathan
King, Daniel
Strickland, Matthew
Goodrich, Austin
Carlisle, Destin
Shergill, Ardaman
O'Reilly, Eileen Mary
Meyerhardt, Jeffrey A.
Shah, Manish A.
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Mayo Clin, Alliance Stat & Data Management Ctr, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Univ Nebraska Med Ctr, Omaha, NE USA
[5] Sanford Hlth, Sioux Falls, SD USA
[6] Northwell Hlth, New Hyde Pk, NY USA
[7] Massachusetts Gen Hosp, Boston, MA USA
[8] Univ Chicago, Alliance Protocol Operat Off, Chicago, IL USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Weill Cornell Med, New York Presbyterian Hosp, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4175
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial
    Ozaki, Yukinori
    Mukohara, Toru
    Tsurutani, Junji
    Takahashi, Masato
    Matsumoto, Koji
    Futamura, Manabu
    Masuda, Norikazu
    Kitano, Shigehisa
    Yoshimura, Kenichi
    Minami, Hironobu
    Takano, Toshimi
    CANCER RESEARCH, 2020, 80 (04)
  • [22] First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
    Hegewisch-Becker, Susanna
    Mendez, Guillermo
    Chao, Joseph
    Nemecek, Radim
    Feeney, Kynan
    Van Cutsem, Eric
    Al-Batran, Salah-Eddin
    Mansoor, Wasat
    Maisey, Nicholas
    Pazo Cid, Roberto
    Burge, Matthew
    Perez-Callejo, David
    Hipkin, R. William
    Mukherjee, Sourav
    Lei, Ming
    Tang, Hao
    Suryawanshi, Satyendra
    Kelly, Ronan J.
    Tebbutt, Niall C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2080 - 2093
  • [23] Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Bourlon, M. T.
    Zurawski, B.
    Oyervides Juarez, V. M.
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Barrios, C. H.
    Richardet, M.
    Pook, D.
    Tomita, Y.
    Escudier, B.
    Zhang, J.
    Simsek, B.
    Apolo, A. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1159 - S1159
  • [24] A phase II randomized trial of gemcitabine plus cisplatin(GP) vs. gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple negative breast cancer
    Gong, Chengcheng
    Cao, Enying
    Wang, Zhonghua
    Zhang, Jian
    Wang, Leiping
    Cao, Jun
    Zhang, Sheng
    Tao, Zhonghua
    Li, Ting
    Zhao, Yannan
    Li, Yi
    Wang, Biyun
    Hu, Xichun
    CANCER RESEARCH, 2018, 78 (04)
  • [25] Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    Miles, D. W.
    de Haas, S. L.
    Dirix, L. Y.
    Romieu, G.
    Chan, A.
    Pivot, X.
    Tomczak, P.
    Provencher, L.
    Cortes, J.
    Delmar, P. R.
    Scherer, S. J.
    BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1052 - 1060
  • [26] Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    D W Miles
    S L de Haas
    L Y Dirix
    G Romieu
    A Chan
    X Pivot
    P Tomczak
    L Provencher
    J Cortés
    P R Delmar
    S J Scherer
    British Journal of Cancer, 2013, 108 : 1052 - 1060
  • [27] Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial
    Yardley, Denise A.
    Dickson, Natalie
    Drosick, David
    Earwood, Chris
    Inhorn, Roger
    Murphy, Patrick
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2016, 16 (03) : 180 - 187
  • [28] First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Cleary, James M.
    Elimova, Elena
    Karamouzis, Michalis
    Bruges, Ricardo
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshi
    Tehfe, Mustapha
    Zander, Thomas
    Kowalyszyn, Ruben
    Pazo-Cid, Roberto
    Schenker, Michael
    Feeny, Kynan
    Wang, Rui
    Lei, Ming
    Chen, Clara
    Nathani, Raheel
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2012 - 2020
  • [29] Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
    Lenz, Heinz-Josef
    Parikh, Aparna
    Spigel, David R.
    Cohn, Allen L.
    Yoshino, Takayuki
    Kochenderfer, Mark
    Elez, Elena
    Shao, Spencer H.
    Deming, Dustin
    Holdridge, Regan
    Larson, Timothy
    Chen, Eric
    Mahipal, Amit
    Ucar, Antonio
    Cullen, Dana
    Baskin-Bey, Edwina
    Kang, Tong
    Hammell, Amy B.
    Yao, Jin
    Tabernero, Josep
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [30] A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
    Tryfonidis, K.
    Boukovinas, I.
    Xenidis, N.
    Christophyllakis, C.
    Papakotoulas, P.
    Politaki, E.
    Malamos, N.
    Polyzos, A.
    Kakolyris, S.
    Georgoulias, V.
    Mavroudis, D.
    BREAST, 2013, 22 (06): : 1171 - 1177
12345